Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines.
We isolated human KB adenocarcinoma cisplatin-resistant (CP-r) cell lines with multidrug-resistance phenotypes because of reduced accumulation of cisplatin and other cytotoxic compounds such as methotrexate and heavy metals. The uptake of horseradish peroxidase (HRPO) and Texas Red dextran was decreased several-fold in KB-CP-r cells, indicating a general defect in fluid-phase endocytosis. In contrast, although EGF receptors were decreased in amount, the kinetics of EGF uptake, a marker of receptor-mediated endocytosis, was similar in sensitive and resistant cells. However, 40-60% of the (125)I-EGF released into the medium after uptake into lysosomes of KB-CP-r cells was TCA precipitable as compared to only 10% released by sensitive cells. These results indicate inefficient degradation of internalised (125)I-EGF in the lysosomes of KB-CP-r cells, consistent with slower processing of cathepsin L, a lysosomal cysteine protease. Treatment of KB cells by bafilomycin A(1), a known inhibitor of the vacuolar proton pump, mimicked the phenotype seen in KB-CP-r cells with reduced uptake of HRPO, (125)I-EGF, (14)C-carboplatin, and release of TCA precipitable (125)I-EGF. KB-CP-r cells also had less acidic lysosomes. KB-CP-r cells were crossresistant to Pseudomonas exotoxin, and Pseudomonas exotoxin-resistant KB cells were crossresistant to cisplatin. Since cells with endosomal acidification defects are known to be resistant to Pseudomonas exotoxin and blocking of endosomal acidification mimics the CP-r phenotype, we conclude that defective endosomal acidification may contribute to acquired cisplatin resistance.
Chauhan
S S
SS
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20842-4254, USA.
Liang
X J
XJ
Su
A W
AW
Pai-Panandiker
A
A
Shen
D W
DW
Hanover
J A
JA
Gottesman
M M
MM
D001692:Biological Transport; D016190:Carboplatin / Q000493:pharmacokinetics; D002294:Carcinoma, Squamous Cell; D045744:Cell Line, Tumor / Q000502:physiology* / Q000648:ultrastructure; D002945:Cisplatin / Q000633:toxicity*; D019008:Drug Resistance, Neoplasm; D004705:Endocytosis / Q000187:drug effects / Q000502:physiology*; D004815:Epidermal Growth Factor / Q000378:metabolism; D006735:Horseradish Peroxidase / Q000493:pharmacokinetics; D006801:Humans; D008247:Lysosomes / Q000187:drug effects / Q000502:physiology*
D004815:Epidermal Growth Factor; D016190:Carboplatin; D006735:Horseradish Peroxidase; D002945:Cisplatin